Ranked #3,992 of 8,699 institutional investors
Avidity Partners Management LP
Dallas, TX
$434M
US stock portfolio at live prices · today +$5.1M (+1.19%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $428M
- Change from Q2 2026
- −$196.5M (−31.47%)
- Positions
- 17 · 0 new, 25 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $60.3M of stock.
Holdings
Q3 2026 13F, live pricesDNTH 37.1%CGON 25.5%ORKA 17.7%JBIO 6.94%ELVN 5.88%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. | 1,899,593 | $161M | 37.1% | Reduced −10% |
| CGON CG Oncology, Inc. | 1,348,948 | $110M | 25.5% | Reduced −4% |
| ORKA Oruka Therapeutics, Inc. | 785,424 | $76.6M | 17.7% | Added +3% |
| JBIO Jade Biosciences, Inc. | 2,000,000 | $30.1M | 6.94% | Added +18% |
| ELVN Enliven Therapeutics, Inc. | 550,000 | $25.5M | 5.88% | Unchanged |
| AKTS Aktis Oncology, Inc. | 484,200 | $7.9M | 1.83% | Unchanged |
| IMUX Immunic, Inc. | 669,941 | $5.0M | 1.14% | Unchanged |
| CATX Perspective Therapeutics, Inc. | 6,067,999 | $4.8M | 1.10% | Reduced −4% |
| MOBI Mobia Medical, Inc. | 324,676 | $3.9M | 0.89% | Reduced −59% |
| PVLA Palvella Therapeutics, Inc. | 20,000 | $2.9M | 0.67% | Reduced −71% |
| NVCT Nuvectis Pharma, Inc. | 100,415 | $2.0M | 0.46% | Reduced −50% |
| MSLE Satellos Bioscience Inc. | 164,019 | $951K | 0.22% | Reduced −58% |
| SENS Senseonics Holdings, Inc. | 100,000 | $890K | 0.21% | Reduced −94% |
| CNTX Context Therapeutics Inc. | 4,060,254 | $685K | 0.16% | Reduced −19% |
| AVLN Avalyn Pharma Inc. | 20,000 | $574K | 0.13% | Reduced −67% |
| SCYX SCYNEXIS, Inc. | 153,613 | $400K | <0.1% | Reduced −41% |
| KPTIQ Karyopharm Therapeutics Inc. | 884,900 | $30K | <0.1% | Reduced −4% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| RGEN Repligen Corporation | 77,800 | $13.2M |
| DXCM DexCom, Inc. | 100,000 | $8.0M |
| TEM Tempus AI, Inc. | 105,000 | $6.3M |
| EHC Encompass Health Corporation | 42,000 | $5.6M |
| VIR Vir Biotechnology, Inc. | 519,300 | $4.6M |
| BSX Boston Scientific Corporation | 80,000 | $3.4M |
| GILD Gilead Sciences, Inc. | 20,000 | $3.3M |
| PODD Insulet Corporation | 24,000 | $3.3M |
| CRL Charles River Laboratories International, Inc. | 10,000 | $3.3M |
| ALMR Alamar Biosciences, Inc. | 110,000 | $3.2M |
| GMAB Genmab A/S | 50,000 | $2.6M |
| GPCR Structure Therapeutics Inc. | 98,000 | $1.7M |
| ABT Abbott Laboratories | 10,000 | $1.0M |
| PHAT Phathom Pharmaceuticals, Inc. | 200,000 | $1.0M |
| KLRA Kailera Therapeutics, Inc. | 80,000 | $926K |
| CRVS Corvus Pharmaceuticals, Inc. | 80,000 | $801K |
| BBIO BridgeBio Pharma, Inc. | 10,000 | $782K |
| NTLA Intellia Therapeutics, Inc. | 75,000 | $714K |
| EVMN Evommune Inc | 75,000 | $543K |
| PTON Peloton Interactive, Inc. | 100,000 | $507K |
| TENX Tenax Therapeutics, Inc. | 265,934 | $370K |
| SVRA Savara Inc. | 50,000 | $261K |
| LEGN Legend Biotech Corporation | 15,000 | $242K |
| TRVI Trevi Therapeutics, Inc. | 6,660 | $91K |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 43,853 | $82K |